| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.3 | 6e-16 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-15 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.22 | 8e-14 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-13 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-12 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-12 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.26 | 3e-12 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-11 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-11 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.22 | 9e-10 |